PubMed · 3746572
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
S Chrai, P Mason, L Mestrandrea, T Myers, D O'Connor, J Palermo, S Rusmin, C Smalley, L Tilton, J Wilson. Decontaminating agents.. https://pubmed.ncbi.nlm.nih.gov/3746572/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The newer fluoroquinolones have broad-spectrum bactericidal activity, excellent oral bioavailability, good tissue penetration and favorable safety and tolerability profiles. A new four-generation classification of the quinolone drugs takes into account the expanded antimicrobial spectrum of the more recently introduced fluoroquinolones and their clinical indications. First-generation drugs (e.g., nalidixic acid) achieve minimal serum levels. Second-generation quinolones (e.g., ciprofloxacin) have increased gram-negative and systemic activity. Third-generation drugs (e.g., levofloxacin) have expanded activity against gram-positive bacteria and atypical pathogens. Fourth-generation quinolone drugs (currently only trovafloxacin) add significant activity against anaerobes. The quinolones can be differentiated within classes based on their pharmacokinetic properties. The new classification can help family physicians prescribe these drugs appropriately.
Explore the source record for details and available documents.
A series of novel 6-O-substituted erythromycin A derivatives has been synthesized. Good in vitro antibacterial activity has been demonstrated for analogues incorporating a variety of structural features. The methodology disclosed is expected to find application in the design of future macrolide antibiotics that target the prevalent bacterial resistance problem.